Espoo, Finland – Orion presented last week at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)...
Latest News
QUINCY, Mass. – The Orphan Drug Act (ODA) celebrates its birthday on January 3. The year 2024 marks 41 years of revolutionizing drug development for rare diseases and helping millions of patients in the process. More than 25 million Americans have some kind of rare disease, defined as a condition...
ELK GROVE VILLAGE, Ill. — Orsini Specialty Pharmacy has been selected by AstraZeneca and Ionis as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN). WAINUA is a subcutaneous injection that can be self-administered,...
ELK GROVE VILLAGE, Ill. – Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA® (tiopronin). Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation...
Osaka, Japan – It might start simply, with a cough or sneeze…but in some cases, the flu virus can make its way to your brain, causing serious symptoms or even death through a disease known as influenza-associated encephalopathy (IAE). Now, in a study published in Acta Neuropathologica, researchers have revealed...
PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ — Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer’s disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation...
Nantes – OSE Immunotherapeutics (FR0012127173) and the French cooperative group ARCAGY-GINECO today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer...
Compared with afatinib, treatment with osimertinib demonstrates better survival outcomes for patients with T790M-positive non-small cell lung cancer (NSCLC) that does not initially respond to initial epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), according to study results published in BMC Pulmonary Medicine. A team of investigators in China conducted a...
Norman, Oklahoma – Researchers at OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences have embarked on a revolutionary new research study that could improve the detection of a deadly disease — pancreatic cancer — and give patients a chance to live longer, healthier lives. The research...
Evanston, Illinois — Women diagnosed with ovarian cancer may initially respond well to chemotherapy, but the majority of them will develop resistance to treatment and die from the disease. Now Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how...